Association between CYP17A1 polymorphisms and response to abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review

We aimed to summarize and clarify the association between cytochrome P450 17α-hydrolase (CYP17A1) polymorphisms and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone. The databases of PubMed, EMBASE, and Web of Science were searched for relevant studies. Overall survival (OS) and/or progression-free survival (PFS) were calculated. Odds ratios (ORs) and/or hazard ratios (HRs) with 95% confidence interval (CI) were utilized to evaluate the strength of the association. A total of 3 studies including 204 patients were analyzed in this systematic review. It was shown that CYP17A1 copy number variations were related to the prognosis of mCRPC patients treated with abiraterone. In addition, rs2486758, a common single-nucleotide polymorphisms (SNPs) in CYP17A1, was significantly associated with a poor biochemical response and a faster biochemical progression. Our systematic review showed that CYP17A1 polymorphisms are associated with response to abiraterone in mCRPC patients. Further research is needed to translate these findings into clinical decisive parameters.

[1]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[2]  C. Kwak,et al.  Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials , 2017, Oncotarget.

[3]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[4]  V. Conteduca,et al.  CYP17A1 Polymorphisms and Clinical Outcome of Castration-Resistant Prostate Cancer Patients Treated with Abiraterone , 2016, The International journal of biological markers.

[5]  F. Saad,et al.  Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. , 2016, European urology.

[6]  D. Generali,et al.  Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. , 2016, Critical reviews in oncology/hematology.

[7]  J. Connell,et al.  Common Polymorphisms at the CYP17A1 Locus Associate With Steroid Phenotype: Support for Blood Pressure Genome-Wide Association Study Signals at This Locus. , 2016, Hypertension.

[8]  G. Scagliotti,et al.  Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. , 2015, Cancer treatment reviews.

[9]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[10]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[11]  D. Amadori,et al.  Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.

[12]  Dustin R. Bunch,et al.  Conversion of abiraterone to D4A drives antitumor activity in prostate cancer , 2015, Nature.

[13]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[14]  F. Saad,et al.  Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). , 2014, European urology.

[15]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[16]  M. Parmar,et al.  Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: Data from >600 patients in the control arm of the STAMPEDE trial (NCT00268476). , 2013 .

[17]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[18]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[19]  C. Sander,et al.  Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. , 2012, Cancer research.

[20]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[21]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[22]  K. Pienta,et al.  Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. , 2012, Cancer research.

[23]  Christian Gieger,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[24]  F. Wang,et al.  CYP17 gene polymorphisms and prostate cancer risk: A meta‐analysis based on 38 independent studies , 2011, The Prostate.

[25]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[26]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[27]  W. Miller,et al.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. , 2011, Endocrine reviews.

[28]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[29]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[30]  D. Koller,et al.  Population genomics of human gene expression , 2007, Nature Genetics.

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[32]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.